SEARCH

SEARCH BY CITATION

References

  • 1
    Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J Cutan Med Surg2009; 13 (Suppl. 2):S6776.
  • 2
    Archier E, Devaux S, Castela E et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol2012; 26 (Suppl. 3):2231.
  • 3
    Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol2005; 152:597615.
  • 4
    Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med2003; 349:201422.
  • 5
    Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol2004; 51:53442.
  • 6
    Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol2006; 55:598606.
  • 7
    Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med2007; 356:58092.
  • 8
    Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet2008; 371:166574.
  • 9
    Abuabara K, Wan J, Troxel AB et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol2013; 68:2629.
  • 10
    Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet2008; 371:167584.
  • 11
    Griffiths CEM, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med2010; 362:11828.
  • 12
    Kimball AB, Papp KA, Wasfi Y et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to five years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol2012; (in press).
  • 13
    Geng D, Shankar G, Schantz A et al. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal2005; 39:36475.
  • 14
    Lebwohl M, Leonardi C, Griffiths CEM et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol2012; 66:73141.
  • 15
    Miniño AM, Murphy SL, Xu J et al. Deaths: final data for 2008. Natl Vital Stat Rep2011; 59:1126.
  • 16
    National Cancer Institute. Surveillance, Epidemiology and End Results. Overview of the SEER program. Available at: http://SEER.cancer.gov/about/overview.html (last accessed 17 January 2013).
  • 17
    Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity2003; 19:6414.
  • 18
    Wakkee M, de Vries E, van den Haak P et al. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol2011; 65:113544.
  • 19
    Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol1999; 140:23742.
  • 20
    Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol2010; 37:220515.
  • 21
    Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature2006; 442:4615.
  • 22
    Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case–control analysis. J Invest Dermatol2009; 129:260412.
  • 23
    Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA2006; 296:173541.
  • 24
    Patel RV, Shelling ML, Prodanovich S et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med2011; 26:103649.
  • 25
    Reich K, Papp KA, Griffiths CEM et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol2012; 11:30012.
  • 26
    Gordon KB, Papp KA, Langley RG et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol2012; 66:74251.
  • 27
    Kimball AB, Szapary P, Mrowietz U et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol2012; 67:7685.
  • 28
    Fieschi C, Casanova JL. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol2003; 33:14614.
  • 29
    van de Vosse E, Ottenhoff TH. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes Infect2006; 8:116773.
  • 30
    Filipe-Santos O, Bustamante J, Chapgier A et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol2006; 18:34761.
  • 31
    Kagami S, Rizzo HL, Kurtz SE et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol2010; 185:545362.
  • 32
    Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science2011; 332:658.
  • 33
    Menter A, Reich K, Gottlieb AB et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol2008; 7:113746.
  • 34
    Leonardi C, Papp K, Strober B et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol2011; 12:32137.
  • 35
    Burmester GR, Panaccione R, Gordon KB et al. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis2013; 72:51724.
  • 36
    Tsai T-F, Chiu H-Y, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol2013; 168:4446.
  • 37
    Pariser DM, Leonardi CL, Gordon K et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol2012; 67:24556.
  • 38
    Papp KA, Poulin Y, Bissonnette R et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol2012; 66:e3345.
  • 39
    Yong M, Schenfeld J, Anthony M, Kimball AB. Incidence rates of malignancies and hospitalized infectious events in psoriasis patients with or without treatment and a general population in the US: 2005–2009. Presented at the American Academy of Dermatology Annual Meeting, San Diego, CA, U.S.A., March 16–20, 2012; abstr. 4586.
  • 40
    Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol2009; 60:100117.
  • 41
    Stricklin SM, Stoecker WV, Malters JM et al. Melanoma in situ in a private practice setting 2005 through 2009: location, lesion size, lack of concern. J Am Acad Dermatol2012; 67:e1059.
  • 42
    Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist2011; 16:896903.
  • 43
    Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol2011; 65:25361.
  • 44
    Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med2005; 353:22629.
  • 45
    Engels EA, Pfeiffer RM, Fraumeni JF et al. Spectrum of cancer risk among US solid organ transplant recipients: the transplant cancer match study. JAMA2011; 306:1891901.
  • 46
    Ahlehoff O, Gislason GH, Jørgensen CH et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J2012; 33:205464.
  • 47
    Mehta NN, Yu Y, Pinnelas R et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med2011; 124:775.e1–6.
  • 48
    Mehta NN, Azfar RS, Shin DB et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J2010; 31:10006.
  • 49
    Micha R, Imamura F, Wyler von Ballmoos M et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol2011; 108:136270.
  • 50
    Westlake SL, Colebatch AN, Baird J et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford)2010; 49:295307.
  • 51
    Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford)2011; 50:51831.
  • 52
    Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol2011; 165:106673.
  • 53
    Wu JJ, Poon K-YT, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol2012; 148:124450.
  • 54
    Reich K, Langley RG, Lebwohl M et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol2011; 164:86272.
  • 55
    Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA2011; 306:86471.
  • 56
    Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol2012; [Epub ahead of print].
  • 57
    Papp KA, Strober B, Augustin M et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol2012; 11:121017.
  • 58
    Burden AD, Warren RB, Kleyn CE et al. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol2012; 166:54554.